Jokic, Vera (59900229100)Vera (59900229100)JokicSavic-Vujovic, Katarina (57217857650)Katarina (57217857650)Savic-VujovicSpasic, Jelena (57195299847)Jelena (57195299847)SpasicStanic, Nemanja (57195304019)Nemanja (57195304019)StanicMarinkovic, Mladen (57222259689)Mladen (57222259689)MarinkovicRadosavljevic, Davorin (55851649000)Davorin (55851649000)RadosavljevicCavic, Milena (39760938900)Milena (39760938900)Cavic2025-06-122025-06-122021https://doi.org/10.1080/14737140.2021.1893694https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102048686&doi=10.1080%2f14737140.2021.1893694&partnerID=40&md5=e6f0b7a882c37d5e285138b30f287916https://remedy.med.bg.ac.rs/handle/123456789/4518Background: The aim of this study was to analyze the prognostic value of pre-treatment hematological parameters in EGFR-mutated non-small cell lung cancer patients treated with tyrosine-kinase inhibitors (TKIs). Patients and methods: Patients with EGFR mutations were treated with EGFR-TKIs in the first line until progression/unacceptable toxicity. Hematological parameters were derived from the absolute baseline differential counts of a complete blood count. The associations between the patients’ and tumor characteristics were analyzed using Pearson Chi-Square, Fisher’s exact, t-test, and Mann–Whitney tests. Cutoff values were determined using ROC curves, and correlation with survival was examined by Kaplan–Meier method and Cox regression. Results: Patients with NMR<12.62 had a longer PFS compared to patients with higher NMR values (12.0 vs. 10.0 months, p = 0.054) and a significantly longer OS (20.0 vs. 11.0 months, p = 0.010). The same parameter was confirmed as a predictors of favorable response in the patient subgroup with activating EGFR mutations. Patients with NLR>2.9 and LMR<2.5 more often presented with paronichia and diarrhea, and patients with PLR>190 more often had paronichia, diarrhea and hyperbilirubinemia. Conclusion: Low baseline value of the hematological parameter NMR has shown potential as a routine, low-cost, and minimally invasive predictor of survival in EGFR-TKI-treated NSCLC patients. © 2021 Informa UK Limited, trading as Taylor & Francis Group.EGFRhematological parameterslung cancertoxicitytyrosine kinase inhibitors